Drug Regulatory Authority of Pakistan (DRAP) on November 10, 2020 has ordered recall of Azomax 500mg FCT, a medicine manufactured by GSK Consumer Healthcare Pakistan Limited, Jamshoro. This happened because of the potential mix-up that can pose potential safety risk to the patients.
By Sayyed Shehzer Abbas
Mixing-up is defined as an unplanned combination of various compounds. A mistake brought about wrongly identifying one material for another. The main reason of a mix-up is human error. A bad judgement or lack of attention to the details of the medicine can end up in a mix-up. Or it can occur through poor communication between personnel.
Azomax is a tablet used to treat infections caused by certain bacteria. It works by stopping bacteria from multiplying. This treatment kills the virus and treats the infections.
DRAP has ordered the manufacturer to recall all the stocks of suspected batch of product and alert their sales officer, suppliers and distributors to issue instructions to the pharmacies and hospitals, point of sales, purchase and use for the return of suspected stocks of product in question.
Moreover, DRAP has ordered the company to report back in 7 days after resolving this issue and removing all the medicines from the suspected stocks.